Journal of Practical Oncology ›› 2022, Vol. 36 ›› Issue (5): 445-451.doi: 10.11904/j.issn.1002-3070.2022.05.010
• Review • Previous Articles Next Articles
WANG Xinghan, LV Yalei
Received:
2022-03-29
Revised:
2022-08-09
Online:
2022-10-28
Published:
2022-11-10
CLC Number:
WANG Xinghan, LV Yalei. Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer[J]. Journal of Practical Oncology, 2022, 36(5): 445-451.
1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. 2 Wang RX,Chen S,Jin X,et al.Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer:loss of HER2 amplification and its impact on response and prognosis[J].Breast Cancer Res Treat,2017,161(2):259-267. 3 Swain SM,Baselga J,Kim SB,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].N Engl J Med,2015,372(8):724-734. 4 Sonnenblick A,Bailey A,Uziely B,et al.Autoimmunity and benefit from trastuzumab treatment in breast cancer:results from the HERA trial[J].Anticancer Res,2019,39(2):797-802. 5 Marty M,Cognettlf,Maraninchi D,et al.Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group[J].J Clin Oncol,2005,23(19):4265-4274. 6 Singer CF,Köstler WJ,Hudelist G.Predicting the efficacy of trastuzumab-based therapy in breast cancer:current standards and future strategies[J].Biochim Biophys Acta,2008,1786(2):105-113. 7 Venkatesan P.Trastuzumab emtansine for HER2-positive breast cancer[J].Lancet Oncol,2016,17(12):528. 8 Koygun GK,Kars MD,Emsen A,et al.Response to trastuzumab and investigation of expression profiles of matrix metalloproteinase-related proteins in primary breast cancer stem cells[J].Clin Exp Med,2021,21(4):447-456. 9 Zong Y,Pegram M.Research advances and new challenges in overcoming triple-negative breast cancer[J].Cancer Drug Resist,2021,4(3):517. 10 Adamczyk A,Kruczak A,Harazin-Lechowska A,et al.Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment[J].Onco Targets Ther,2018,11:4525-4535. 11 Wu Z,Xu S,Zhou L,et al.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting[J].Onco Targets Ther,2018,11:801-808. 12 Cordo Russo RI,Beguelin W,Flaqué D,et al.Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance[J].Oncogene,2015,34(26):3413-3428. 13 Saranya C,Jeff S,Heshan L,et al.High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2 -positive metastatic breast cancer NCCTG N0337 and NCCTG 98-32-52(Alliance)[J].Clin Cancer Res,2018,24(13):3053-3058. 14 Murad R,Avanes A,Ma X,et al.Transcriptome and chromatin landscape changes associated with trastuzumab resistance in HER2+ breast cancer cells[J].Gene,2021,799(5):145808. 15 Wimana Z,Gebhart G,Guiot T,et al.N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging[J].Oncotarget,2017,8(34):56185-56198. 16 Keegan NM,Furney SJ,Walshe JM,et al.Phase Ib Trial of copanlisib,a phosphoinositide-3 kinase(PI3K)inhibitor,with trastuzumab in advanced pre-treated HER2-positive breast cancer“PantHER”[J].Cancers,2021,13(6):1225. 17 Areti S,Martha Z,Galatea K,et al.A comprehensive molecular analysis of in vivo isolated EpCAM-positive circulating tumor cells in breast cancer[J].Clin Chim,2021,67(10):1395-1405. 18 Yokoyama D,Hisamori S,Deguchi Y,et al.PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma[J].Sci Rep,2021,11(1):9013. 19 O'Brien NA,McDonald K,Tong L,et al.Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT[J].Clin Cancer Res,2014,20(13):3507-3520. 20 Sun Y,Li C,Pang S,et al.Kinase–substrate edge biomarkers provide a more accurate prognostic prediction in ER-negative breast cancer[J].Genomics Proteomics Bioinformatics,2021,18(5):525-538. 21 Daverey A,Drain AP,Kidambi S.Physical intimacy of breast cancer cells with mesenchymal stem cells elicits trastuzumab resistance through Src activation[J].Sci Rep,2015,5(1):13744. 22 孔鸿儒,戴胜杰,陈豪,等.α-龙葵碱通过WNT信号通路抑制曲古抑菌素A-耐药人胰腺癌细胞的上皮-间质转化进程[J].肝胆胰外科杂志,2020,32(2):89-96. 23 师锐赞,何倚帆,牛亚楠,等.上皮黏附分子通过诱导EMT促乳腺癌转移和耐药[J].中国药理学通报,2021,37(7):934-939. 24 Shu X,Hildebrandt MA,Gu J,et al.MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity[J].Brit J Cancer,2017,116(1):77-84. 25 Sajadimajd S,Yazdanparast R,Akram S.Involvement of numb-mediated HIF-1 inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells[J].Tumour Biol,2016,37(4):5413- 5426. 26 Eto K,Iwatsuki M,Watanabe M,et al.The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab[J].Ann Surg Oncol,2014,21(1):343-350. 27 Tehrani SS,Zaboli E,Sadeghi F,et al.MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER2 positive breast cancer patients[J].Bio Medicine,2021,11(2):30-39. 28 Han M,Qian X,Cao H,et al.LncRNA ZNF649-AS1 induces trastuzumab resistance by promoting ATG5 expression and autophagy[J].Mol Ther,2020,28(11):2488-2502. 29 Tan AR,Im SA,Mattar A,et al.Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer(FeDeriCa):a randomised,open-label,multicentre,non-inferiority,phase 3 study[J].Lancet Oncol,2021,22(1):85-97. 30 Díaz-Acedo R,Artacho-Criado S,Galván-Banqueri M,et al.Real world study of pertuzumab-trastuzumab chemotherapy versus trastuzumab-chemotherapy in neoadjuvant treatment of breast cancer[J].Farm Hosp,2020,44(3):96-99. 31 Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].New Eng J Med,2012,367(19):1783-1791. 32 Welslau M,Diéras V,Sohn JH,et al.Patient-reported outcomes from EMILIA,a randomized phase 3 study of trastuzumab emtansine(T-DM1)versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer[J].Cancer,2014,120(5):642-651. 33 Krop IE,Kim SB,Gonzlez-Martín A,et al.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(7):689-699. 34 刘婷,陈蕾,于力.曲妥珠单抗共轭复合物对HER2阳性乳腺癌疗效及用药安全性的Meta分析[J].中华肿瘤防治杂志,2021,28(17):1345-1354. 35 Modi S,Saura C,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-positive breast cancer[J].N Engl J Med,2020,382(7):610-621. 36 Cortés J,Kim SB,Chung WP,et al.LBA1 trastuzumab deruxtecan(T-DXd)vs trastuzumab emtansine(T-DM1)in patients(pts)with HER2+ metastatic breast cancer(mBC):results of the randomized phase III DESTINY-Breast03 study[J].Ann Oncol,2021,32:1287-1288. 37 Zhang J,Ji D,Shen W,et al.Abstract PD8-04:Safety and anti-tumor activity of ARX788 in HER2-positive metastatic breast cancer patients whose disease is resistant/refractory to HER2 targeted agents(trastuzumab,ADCs,TKIs,and bispecific antibodies):ACE-Breast-01 trial results[J].Cancer Res,2022,82(4 Suppl):PD8-04. 38 Wang J,Liu Y,Zhang Q,et al.RC48-ADC,a HER2-targeting antibody-drug conjugate,in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer:a pooled analysis of two studies[J].J Clin Oncol,2021,39(15 Suppl):1022. 39 Xu B,Wang J,Zhang Q,et al.An open-label,multicenter,phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer[J].J Clin Oncol,2018,36(15):1028. 40 Xu B,Wang J,Fang J,et al.Abstract PD4-06:early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer[J].Cancer Res,2020,80(4):10-14. 41 Gong J,Shen L,Wang W,et al.Safety,pharmacokinetics and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer[J].J Clin Oncol,2018,36(15):16059. 42 Rugo HS,Pegram MD,Gradishar WJ,et al.SOPHIA:a phase 3,randomized study of margetuximab(M)plus chemotherapy(CTX)vs trastuzumab(T)plus CTX in the treatment of patients with HER2+ metastatic breast cancer(MBC)[J].J Clin Oncol,2016,34(15):630. 43 Manich CS,O'Shaughnessy J,Aftimos PG,et al.LBA15 primary outcome of the phase III SYD985.002/TULIP trial comparing vic trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer[J].Ann Oncol,2021,32:1288. 44 Hu X,Zhang J,Liu R,et al.Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors[J].J Clin Oncol,2021,39(15):1024. 45 黄文发,严颖,张如艳,等.曲妥珠单抗和拉帕替尼在辅助曲妥珠单抗治疗后一线复发的HER2阳性晚期乳腺癌治疗中疗效的比较[J].肿瘤,2020,40(9):641-649. 46 Nishimura R,Toh U,Tanaka M,et al.Role of HER2-related biomarkers(HER2,p95HER2,HER3,PTEN,and PIK3CA)in the efficacy of lapatinib plus capecitabine in HER2-positive advanced breast cancer refractory to trastuzumab[J].Oncology,2017,93(1):51-61. 47 Chan A,Moy B,Mansi J,et al.Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial[J].Clin Breast Cancer,2020,21(1):80-91. 48 Blackwell KL,Zaman K,Tkaczuk KHR,et al.Neratinib in combination with trastuzumab for the treatment of patients with advanced HER2-positive breast cancer:a phase I/II study[J].Nat Rev Cancer,2019,19(2):97-104. 49 Freedman RA,Gelman RS,Wefel JS,et al.Translational breast cancer research consortium(TBCRC)022:a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases[J].J Clin Oncol,2016,34(9):945-952. 50 André F,O'Regan R,Ozguroglu M,et al.Everolimus for women with trastuzumab-resistant,HER2-positive,advanced breast cancer(BOLERO-3):a randomised,double-blind,placebo- controlled phase 3 trial[J].Lancet Oncol,2014,15(6):580-591. 51 Keck S,Glencer AC,Rugo HS.Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer[J].Future Oncol,2012,8(11):1383-1396. 52 Vernieri C,Corti F,Nichetti F,et al.Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer:targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications[J].Breast Cancer Res,2020,22(1):1-13. 53 Mezynski MJ,Farrelly AM,Cremona M,et al.Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer[J].J Transl Med,2021,19(1):184. 54 Wisinski KB,Tevaarwerk AJ,Burkard ME,et al.Phase I study of an AKT inhibitor(MK-2206)combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer[J].Clin Cancer Res,2016,22(11):2659-2667. |
[1] | SUN Xinglu, CHEN Che. Research progress of Egr1 in liver cancer [J]. Journal of Practical Oncology, 2022, 36(5): 435-439. |
[2] | LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 477-482. |
[3] | LI Bo, PENG Xiaolin, WANG Shanshan, LI Gairui, ZHAO Dan, PENG Ji. Comparative study on application effect of two risk assessment models in screening colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 197-202. |
[4] | WANG Yang, LI Guodong, TANG Qingchao, LIU Ming. Research progress of acidosis in colorectal malignant tumors [J]. Journal of Practical Oncology, 2022, 36(1): 74-78. |
[5] | LI Yujun, LIU Liyang, XIAO Juanjuan, XUE Hua. Prognostic stratification and treatment progress in elderly patients with newly diagnosed multiple myeloma [J]. Journal of Practical Oncology, 2022, 36(1): 84-88. |
[6] | TUO Jiyu, ZHANG Xia, HE Xiaomei, JIANG Wenzhen, FENG Jueping, JIN Xia, ZHANG Min, WEI Shaozhong. Analysis of the screening results of the urban cancer early diagnosis and treatment project in Hubei province from 2018 to 2019 [J]. Journal of Practical Oncology, 2021, 35(4): 297-301. |
[7] | LI Qingyu, YANG Lei, ZHANG Xi, LIU Shuo, LI Huichao, ZHANG Qian, CHENG Yangyang, JI Jiafu, WANG Ning. Discussion on the management of early diagnosis and treatment for cancer under the coronavirus disease(COVID-19) [J]. Journal of Practical Oncology, 2021, 35(4): 302-306. |
[8] | HU Yang, ZHANG Qingyuan. Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer [J]. Journal of Practical Oncology, 2021, 35(2): 184-187. |
[9] | BI Jiaqing, QIN Qian, MA Huihan, MA Meijie, FENG Qinmei. Research progress of threonine and tyrosine kinase in tumor [J]. Journal of Practical Oncology, 2021, 35(2): 188-192. |
[10] | BAI Yibing, YANG Jiani, FANG Lin, ZHANG Yanqiao. Research progress of wild-type gastrointestinal stromal tumors [J]. Journal of Practical Oncology, 2020, 34(6): 524-529. |
[11] | XIAO Haifan, YAN Shipeng, CAO Shiyu, LI Na, XU Kekui, ZOU Yanhua, DENG Hongyu, YANG Wenjuan, SHI Zhaohui, LIAO Xianzhen. Summary for design of early diagnosis and treatment of oral cancer in Hunan province [J]. Journal of Practical Oncology, 2020, 34(6): 544-548. |
[12] | ZUO Rui, JIN Lu, LIU Li, LIU Xiaojia, ZHAO Pengyu, XIANG Xiaoyan. Research progress of miR-409-3p and tumor [J]. Journal of Practical Oncology, 2020, 34(6): 554-559. |
[13] | ZHAO Yingxin, QIN Ling. Research progress of metformin and multiple myeloma [J]. Journal of Practical Oncology, 2020, 34(5): 476-479. |
[14] | ZHANG Rui, LI Zhigao. Clinical research progress of mucinous breast cancer [J]. Journal of Practical Oncology, 2020, 34(4): 377-381. |
[15] | LI Hui,PANG Da. Clinicopathological characteristics and adjuvant treatment of triple positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 262-265. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||